As filed with the Securities and Exchange Commission on July 2, 2015

Registration No. 333-189002

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

 

POST-EFFECTIVE AMENDMENT NO. 1
TO

FORM S-8

 

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

INVIVO THERAPEUTICS HOLDINGS CORP.

(Exact name of registrant as specified in its charter)

 

Nevada

 

36-4528166

(State or other jurisdiction of

 

(I.R.S. Employer Identification No.)

incorporation or organization)

 

 

 

One Kendall Square, Suite B14402

Cambridge, Massachusetts 02139

(Address of Principal Executive Offices)(Zip Code)

 

InVivo Therapeutics Holdings Corp. 2010 Equity Incentive Plan

(Full title of the plan)

 

Steven McAllister
Chief Financial Officer
InVivo Therapeutics Holdings Corp.

One Kendall Square, Suite B14402

Cambridge, Massachusetts 02139

(Name and address of agent for service)

 

(617) 863-5500

(Telephone number, including area code, of agent for service)

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer

o

 

Accelerated filer

x

Non-accelerated filer

o (Do not check if a smaller reporting company)

 

Smaller Reporting Company

o

 

 

 



 

EXPLANATORY NOTE

 

On May 31, 2013, the Registrant filed Registration Statement on Form S-8 (File No.: 333-189002) (the “Form S-8”) registering 1,125,000 shares (on a post-split basis) of the Registrant’s common stock, $0.00001 par value per share (the “Shares”), to be issued to participants under the Registrant’s 2010 Equity Incentive Plan (the “2010 Plan”).

 

On June 16, 2015, the Registrant’s stockholders approved the InVivo Therapeutics Holdings Corp. 2015 Equity Incentive Plan (the “2015 Plan”).  Pursuant to the 2015 Plan, any shares of Common Stock that remain available for issuance under the 2010 Plan as of June 16, 2015 are to be included in the number of shares of Common Stock available for issuance under the 2015 Plan.  No future grants will be made under the 2010 Plan.

 

This Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 is being filed in order to deregister all Shares that were registered under the Form S-8 and remain unissued under the Plan.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Cambridge, Commonwealth of Massachusetts, on July 2, 2015.

 

 

INVIVO THERAPEUTICS HOLDINGS CORP.

 

 

 

 

 

By:

/s/ Steven F. McAllister

 

 

Steven F. McAllister

 

 

Chief Financial Officer

 

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the date indicated:

 

Signature

 

Title

 

Date

 

 

 

 

 

/s/ Mark D. Perrin

 

Chief Executive Officer and Chairman of the Board

 

July 2, 2015

Mark D. Perrin

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Steven F. McAllister

 

Chief Financial Officer and Treasurer

 

July 2, 2015

Steven F. McAllister

 

(Principal Financial Officer and

 

 

 

 

Principal Accounting Officer)

 

 

 

 

 

 

 

/s/ Kenneth DiPietro

 

Director

 

July 2, 2015

Kenneth DiPietro

 

 

 

 

 

 

 

 

 

/s/ Daniel R. Marshak

 

Director

 

July 2, 2015

Daniel R. Marshak

 

 

 

 

 

 

 

 

 

/s/ John A. McCarthy, Jr.

 

Director

 

July 2, 2015

John A. McCarthy, Jr.

 

 

 

 

 

 

 

 

 

s/ C. Ann Merrifield

 

Director

 

July 2, 2015

C. Ann Merrifield

 

 

 

 

 

 

 

 

 

/s/ Richard J. Roberts

 

Director

 

July 2, 2015

Richard J. Roberts

 

 

 

 

 

3